Development and characterization of AXT@metal-organic framework: A biocompatible, pH-responsive nanocarrier for targeted axitinib delivery in MCF-7 cancer cells.

Cancer remains a major global health challenge, characterized by low survival rates and significant side effects from conventional treatments. The metal-organic frameworks (MOFs) offer distinctive features that make them highly suitable for medical innovations. This study presents the development of MOFs as nanocarriers for the anticancer drug axitinib (AXT) to address these issues.

3D-QSAR of novel phosphodiesterase-4 inhibitors by genetic function approximation.

Phosphodiesterase-4 (PDE 4) enzyme has emerged as an invaluable target for the treatment of asthma, chronic obstructive pulmonary disease and rheumatoid arthritis. These findings have generated widespread interest in PDE-4 inhibitors as a potential molecular target for the development of new anti-inflammatory drugs. A series of N-substituted cis-tetra- and cis-hexahydrophthalazinone derivatives have been reported as novel, selective PDE-4 inhibitors with potent anti-inflammatory activity.

Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl)pyrimidines as COX-2 inhibitors.

Cyclooxygenase-2 (COX-2) inhibitors are widely used for the treatment of pain and inflammatory disorders such as rheumatoid arthritis and osteoarthritis. A series of novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives has been reported as COX-2 inhibitors. In order to understand the structural requirement of these COX-2 inhibitors, a ligand-based pharmacophore and atom-based 3D-QSAR model have been developed.